Nanoparticles in Targeted Alpha Therapy

Recent advances in the field of nanotechnology application in nuclear medicine offer the promise of better therapeutic options. In recent years, increasing efforts have been made on developing nanoconstructs that can be used as carriers for immobilising alpha (α)-emitters in targeted drug delivery....

Full description

Bibliographic Details
Main Authors:	Agnieszka Majkowska-Pilip, Weronika Gawęda, Kinga Żelechowska-Matysiak, Kamil Wawrowicz, Aleksander Bilewicz
Format:	Article
Language:	English
Published:	MDPI AG 2020-07-01
Series:	Nanomaterials
Subjects:	α-emitters radiopharmaceuticals nanoparticles nanomedicine targeted therapy tumour
Online Access:	https://www.mdpi.com/2079-4991/10/7/1366

id	doaj-c34e436ac5ef45eb86064cbd4a28863a
record_format	Article
spelling	doaj-c34e436ac5ef45eb86064cbd4a28863a2020-11-25T03:02:57ZengMDPI AGNanomaterials2079-49912020-07-01101366136610.3390/nano10071366Nanoparticles in Targeted Alpha TherapyAgnieszka Majkowska-Pilip0Weronika Gawęda1Kinga Żelechowska-Matysiak2Kamil Wawrowicz3Aleksander Bilewicz4Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, PolandCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, PolandCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, PolandCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, PolandCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, PolandRecent advances in the field of nanotechnology application in nuclear medicine offer the promise of better therapeutic options. In recent years, increasing efforts have been made on developing nanoconstructs that can be used as carriers for immobilising alpha (α)-emitters in targeted drug delivery. In this publication, we provide a comprehensive overview of available information on functional nanomaterials for targeted alpha therapy. The first section describes why nanoconstructs are used for the synthesis of α-emitting radiopharmaceuticals. Next, we present the synthesis and summarise the recent studies demonstrating therapeutic applications of α-emitting labelled radiobioconjugates in targeted therapy. Finally, future prospects and the emerging possibility of therapeutic application of radiolabelled nanomaterials are discussed.https://www.mdpi.com/2079-4991/10/7/1366α-emittersradiopharmaceuticalsnanoparticlesnanomedicinetargeted therapytumour
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Agnieszka Majkowska-Pilip Weronika Gawęda Kinga Żelechowska-Matysiak Kamil Wawrowicz Aleksander Bilewicz
spellingShingle	Agnieszka Majkowska-Pilip Weronika Gawęda Kinga Żelechowska-Matysiak Kamil Wawrowicz Aleksander Bilewicz Nanoparticles in Targeted Alpha Therapy Nanomaterials α-emitters radiopharmaceuticals nanoparticles nanomedicine targeted therapy tumour
author_facet	Agnieszka Majkowska-Pilip Weronika Gawęda Kinga Żelechowska-Matysiak Kamil Wawrowicz Aleksander Bilewicz
author_sort	Agnieszka Majkowska-Pilip
title	Nanoparticles in Targeted Alpha Therapy
title_short	Nanoparticles in Targeted Alpha Therapy
title_full	Nanoparticles in Targeted Alpha Therapy
title_fullStr	Nanoparticles in Targeted Alpha Therapy
title_full_unstemmed	Nanoparticles in Targeted Alpha Therapy
title_sort	nanoparticles in targeted alpha therapy
publisher	MDPI AG
series	Nanomaterials
issn	2079-4991
publishDate	2020-07-01
description	Recent advances in the field of nanotechnology application in nuclear medicine offer the promise of better therapeutic options. In recent years, increasing efforts have been made on developing nanoconstructs that can be used as carriers for immobilising alpha (α)-emitters in targeted drug delivery. In this publication, we provide a comprehensive overview of available information on functional nanomaterials for targeted alpha therapy. The first section describes why nanoconstructs are used for the synthesis of α-emitting radiopharmaceuticals. Next, we present the synthesis and summarise the recent studies demonstrating therapeutic applications of α-emitting labelled radiobioconjugates in targeted therapy. Finally, future prospects and the emerging possibility of therapeutic application of radiolabelled nanomaterials are discussed.
topic	α-emitters radiopharmaceuticals nanoparticles nanomedicine targeted therapy tumour
url	https://www.mdpi.com/2079-4991/10/7/1366
work_keys_str_mv	AT agnieszkamajkowskapilip nanoparticlesintargetedalphatherapy AT weronikagaweda nanoparticlesintargetedalphatherapy AT kingazelechowskamatysiak nanoparticlesintargetedalphatherapy AT kamilwawrowicz nanoparticlesintargetedalphatherapy AT aleksanderbilewicz nanoparticlesintargetedalphatherapy
_version_	1724687543932289024

Nanoparticles in Targeted Alpha Therapy

Similar Items